OBSV - OBSV STOCK NEWS

ObsEva SA has announced the appointment of Annette Clancy as Chair of the Board of Directors, effective May 18, 2022. Clancy, who has been on the Board since 2013 and previously served as Chair from 2013 to 2016, succeeds Dr. Frank Verwiel, who is retiring. CEO Brian O’Callaghan expressed confidence in Clancy's leadership as the company prepares for its first product approvals and commercial launch. Clancy has over 30 years of experience in the pharmaceutical industry, significantly in business development.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN) reported that shareholders approved all proposals at its 2022 Annual General Meeting held on May 18, 2022. Key approvals included:

• Annual and Consolidated Financial Statements for Fiscal Year 2021
• Discharge to Board Members and Executive Committee for 2021
• Compensation for the Board and Executive Committee
• Increase in Authorized and Conditional Share Capital
• Re-election of PricewaterhouseCoopers as Auditors

These decisions are critical for the company's ongoing governance and financial strategies.

ObsEva SA (NASDAQ: OBSV) reported significant advancements in their development of linzagolix for uterine fibroids and endometriosis. The company received a positive CHMP opinion for marketing authorization in Europe and anticipates a PDUFA date of September 13, 2022, for the U.S. NDA. Financially, ObsEva ended Q1 2022 with $57.6 million in cash, down from $20 million in net losses. R&D expenses dropped to $5.6 million, while general and administrative costs rose to $7.2 million. The company is also preparing for product launches in collaboration with Theramex and Syneos Health.

ObsEva SA (NASDAQ: OBSV) announced positive developments for its linzagolix product aimed at treating uterine fibroids and endometriosis. The CHMP provided a positive opinion for marketing authorization in Europe while the FDA's PDUFA target action date is set for September 13, 2022.

Financially, ObsEva reported Q1 2022 net loss of $11.8 million ($0.14/share), an improvement from $20 million in Q1 2021. Cash and equivalents rose to $57.6 million, attributed to various funding activities. R&D expenses decreased to $5.6 million, while G&A expenses increased to $7.2 million. Overall, ObsEva is progressing towards significant commercialization efforts in women’s health.

ObsEva SA (NASDAQ: OBSV) announced a corporate update to be presented at the H.C. Wainwright Global Investment Conference, scheduled virtually and in Miami from May 23 – 26, 2022. The presentation will be available on-demand starting at 10:30 a.m. EST on May 24, 2022. ObsEva focuses on developing and commercializing therapies for women’s reproductive health, addressing conditions like uterine fibroids and endometriosis. Interested parties can access the webcast through the conference portal or via the company's website under the “Events Calendar” section.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company focused on women's health, announced a corporate update presentation at the H.C. Wainwright Global Investment Conference. The event will occur virtually and in Miami, Florida, from May 23 – 26, 2022. The presentation will be available on-demand starting at 10:30 a.m. EST on May 24, 2022. Investors can access the webcast through the H.C. Wainwright conference portal or under the 'Events Calendar' on ObsEva’s website. The company focuses on treatments for uterine fibroids, endometriosis, and preterm labor.

ObsEva is preparing to host a conference call on May 17, 2022, at 8:00 a.m. ET to discuss its financial results for Q1 2022, concluding March 31. Participants can join the call via telephone or through a live webcast, which will also be archived for 30 days. ObsEva focuses on developing therapies for women's health, with a pipeline targeting uterine fibroids, endometriosis, and preterm labor. The company's stock is traded on NASDAQ under the ticker OBSV.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN) announced a conference call on May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the first quarter ending March 31, 2022, and to provide a business update. Participants can join via telephone or webcast, which will be archived on their website. ObsEva focuses on developing therapies for women’s health, including treatments for uterine fibroids, endometriosis, and preterm labor, establishing a late-stage clinical pipeline.

ObsEva SA (NASDAQ: OBSV) presented clinical data from the PRIMROSE Phase 3 studies of linzagolix at the ACOG Annual Meeting. The treatment aimed at heavy menstrual bleeding associated with uterine fibroids showed sustained quality of life improvements, with positive outcomes maintained at 52 weeks and partial recovery noted after treatment cessation. Linzagolix demonstrated a low incidence of alopecia and improved hemoglobin levels in patients with severe anemia. The studies involved around 1,100 women across the U.S. and Europe, indicating linzagolix's potential as a leading therapy in women's health.